1
|
Ayulo V, Moronge D, Connor G, Mellot E, Ogbi S, Gillis E, Sullivan J, Faulkner J. Female rats with history of acute kidney injury develop adverse maternal and fetal events during pregnancy. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00603-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
2
|
Lapthorn A, Ilg M, Sullivan J, Dziewulski P, Cellek S. 616 Investigating if hydroxypyridone anti-fungals can target already established myofibroblasts in an in vitro model of hypertrophic scarring. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
3
|
Keir M, Tarr C, McFadden C, Durupt G, Newman L, Sullivan J, Balon Y, Prieur T, Patton D, Jenkins J, Alvarez N, Colbert J, Guron N, Reynolds S, Myers K. DETERMINING RESEARCH PRIORITIES WITH TEEN AND ADULT CONGENITAL HEART DISEASE PATIENTS: A MIXED METHODS STUDY. Can J Cardiol 2022. [DOI: 10.1016/j.cjca.2022.08.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
4
|
Lurier E, Sullivan J, Skouras S, Massa V, Fitzgerald M, Wang A, Zheng X, Walther D, Browne C, Dey J, McDonald A, Gollob J, Mainolfi N, Slavin A, Campbell V. LB993 Kinetics of IRAK4 degradation and impact on functional response in circulating immune cells and skin cell subsets. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.1017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
5
|
Hubeau C, Sullivan J, Brown C, Mayo M, Dixit V, Enerson B, Rong H, Yang B, De Savi C, Gollob J, Mainolfi N, Slavin A. OP0080 STAT3 DEGRADERS INHIBIT Th17 DEVELOPMENT AND CYTOKINE PRODUCTION RESULTING IN PROFOUND INHIBITION OF COLLAGEN-INDUCED AUTOIMMUNE MURINE ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundSignal transducer and activator of transcription 3 (STAT3) is a transcription factor that belongs to a class of targets devoid of catalytic function, thus deemed “undruggable” by standard modalities such as small molecule inhibitors or biologics. STAT3 can be activated by various receptor- and non-receptor tyrosine kinases, playing a critical role in activation pathways triggered by cytokines, hormones, and growth factors, making it an attractive target for the treatment of inflammatory diseases.ObjectivesKymera has developed heterobifunctional molecules that selectively target STAT3 for degradation and elimination by the ubiquitin-proteasome pathway. We sought to evaluate the pharmacologic potential of these STAT3 degraders through in vitro and in vivo studies relevant to human autoimmune disease, including murine collagen-induced arthritis.MethodsWe evaluated the impact of STAT3 degraders on the activation of human monocytes, dermal fibroblasts, CD4+ T cells, and PBMC by LPS, IL-6/IL-6R, IL-21, IL-23, as well as anti-CD3/CD28 plus a cocktail of cytokines and antibodies. STAT3 degradation and pSTAT3 inhibition were determined in comparison to a JAK1/2 small molecule inhibitor. Inhibition of cytokines, chemokines, and collagen release, as well as Th17 (CD4+CD25-RORγt+CXCR6+) and Treg (CD4+CD25+CD127lowFOXP3+) expansion were used as in vitro efficacy assays. Finally, STAT3 degraders were tested in vivo, in a mechanistic (IL-6 challenge) as well as a disease model (murine CIA) relevant to rheumatology indications.ResultsSTAT3 degraders showed broad and potent activity in-vitro against TLR receptor and cytokine-induced activation of immune and stromal cells, including soluble mediator release such as MCP-1/CCL2 and Collagen1a1. STAT3 degradation in CD4+ T cells robustly inhibited the development of Th17 cells, abrogating IL-17, IL-22, IL-8/CXCL8, and TNFα production, and increased Treg numbers in a manner superior to JAK1/2 inhibition. In mice injected with IL-6, plasma levels of serum amyloid A were dose-dependently suppressed by STAT3 degradation. In the murine collagen-induced arthritis model, STAT3 degradation resulted in robust, dose-dependent delay of disease onset and decreased disease incidence, clinical scores, local cytokine expression (paws) and histopathological scores, including the complete alleviation of periosteal bone growth.ConclusionThese data demonstrate the broad activity of STAT3 degradation in alleviating autoimmune inflammation in models relevant to human disease. Targeted protein degradation of STAT3 thus represents a novel therapeutic approach to treating autoimmune/autoinflammatory diseases such as rheumatoid arthritis.Disclosure of InterestsCedric Hubeau Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Jeffrey Sullivan Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Crystal Brown Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Michele Mayo Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Vaishali Dixit Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Bradley Enerson Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Haojing Rong Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Bin Yang Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Chris De Savi Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Jared Gollob Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Nello Mainolfi Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Anthony Slavin Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics.
Collapse
|
6
|
Campbell K, Velazquez O, Sullivan J, Lipshultz L. Finasteride-Associated Suicide and Depression in Men Treated for Hypogonadism and Impotence. J Sex Med 2022. [DOI: 10.1016/j.jsxm.2022.01.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
7
|
Campbell K, Velazquez O, Sullivan J, Lipshultz L. Is Testosterone Really Your Sex Hormone: Sexual practices as Defined by Testosterone Concentration. J Sex Med 2022. [DOI: 10.1016/j.jsxm.2022.01.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
8
|
Sullivan J, Woo C, Kaushal N, Karve S, Bhat B, DeRosa F, Sun G, Paksa A, Androsavich J, Wooster R. 590: A lipid nanoparticle–based delivery system for the treatment of CF. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)02013-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Lewis ME, Simpson P, Mori J, Jubb B, Sullivan J, McFadyen L, van der Ryst E, Craig C, Robertson DL, Westby M. V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens. Antivir Chem Chemother 2021; 29:20402066211030380. [PMID: 34343443 PMCID: PMC8369958 DOI: 10.1177/20402066211030380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Viruses from 15 of 35 maraviroc-treated participants with virologic failure and CCR5-tropic (R5) virus in the MOTIVATE studies at Week 24 had reduced maraviroc susceptibility. On-treatment amino acid changes were observed in the viral envelope glycoprotein 120 third variable (V3)-loop stems and tips and differed between viruses. No amino acid change reliably predicted reduced susceptibility, indicating that resistance was genetic context-dependent. Through Week 24, poor adherence was associated with maraviroc-susceptible virologic failure, whereas reduced maraviroc susceptibility was associated with suboptimal background regimen activity, highlighting the importance of overall regimen activity and good adherence. Predictive values of pretreatment V3-loop sequences containing these Week 24 mutations or other variants present at >3% in pretreatment viruses of participants with virologic failure at Week 48 were retrospectively assessed. Week 48 clinical outcomes were evaluated for correlates with pretreatment V3-loop CCR5-tropic sequences from 704 participants (366 responders; 338 virologic failures [83 with R5 virus with maraviroc susceptibility assessment]). Seventy-five amino acid variants with >3% prevalence were identified among 23 V3-loop residues. Previously identified variants associated with resistance in individual isolates were represented, but none were associated reliably with virologic failure alone or in combination. Univariate analysis showed virologic-failure associations with variants 4L, 11R, and 19S (P < 0.05). However, 11R is a marker for CXCR4 tropism, whereas neither 4L nor 19S was reliably associated with reduced maraviroc susceptibility in R5 failure. These findings from a large study of V3-loop sequences confirm lack of correlation between V3-loop genotype and clinical outcome in participants treated with maraviroc.Clinical trial registration numbers (ClinicalTrials.gov): NCT00098306 and NCT00098722.
Collapse
Affiliation(s)
- M E Lewis
- Pfizer Global Research and Development, Sandwich Labs, Sandwich, Kent, UK.,The Research Network Ltd, Sandwich, Kent, UK
| | - P Simpson
- Pfizer Global Research and Development, Sandwich Labs, Sandwich, Kent, UK.,AstraZeneca, Cambridge, UK
| | - J Mori
- Pfizer Global Research and Development, Sandwich Labs, Sandwich, Kent, UK.,hVIVO, Queen Mary BioEnterprise Innovation Centre, London, UK
| | - B Jubb
- Pfizer Global Research and Development, Sandwich Labs, Sandwich, Kent, UK
| | - J Sullivan
- Pfizer Global Research and Development, Sandwich Labs, Sandwich, Kent, UK.,Cytel, London, UK
| | - L McFadyen
- Pfizer Inc, Pharmacometrics, Sandwich, UK
| | - E van der Ryst
- Pfizer Global Research and Development, Sandwich Labs, Sandwich, Kent, UK.,The Research Network Ltd, Sandwich, Kent, UK
| | - C Craig
- Pfizer Global Research and Development, Sandwich Labs, Sandwich, Kent, UK.,The Research Network Ltd, Sandwich, Kent, UK
| | - D L Robertson
- MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
| | - M Westby
- Pfizer Global Research and Development, Sandwich Labs, Sandwich, Kent, UK.,Centauri Therapeutics Limited, Discovery Park, Kent, UK
| |
Collapse
|
10
|
Abstract
Fenfluramine hydrochloride, initially utilized as a weight loss drug in the 1970s and later removed from the market for adverse cardiopulmonary side effects, has since been repurposed as an antiseizure medicine (ASM). The potential antiseizure effects of fenfluramine were first identified in patients with photosensitive epilepsy in the 1980s but it was not rigorously explored as a treatment option until 30 years later. Compared with other ASMs, fenfluramine offers a novel mechanism by acting on serotonin and σ1 receptors, demonstrated in vitro and in vivo in animal models of Dravet syndrome. Results from a large double-blind, placebo-controlled trial demonstrated robust efficacy for seizure reduction in patients with Dravet syndrome, and met its primary endpoint with the 0.7 mg/kg/day fenfluramine treatment group experiencing a 62.3% or greater reduction in mean monthly convulsive seizure frequency (MCSF) compared with placebo. Here we provide a comprehensive review of the preclinical and clinical activity of fenfluramine, a recently approved drug for treatment of epilepsy in patients with Dravet syndrome.
Collapse
Affiliation(s)
- J Sullivan
- University of California, San Francisco (UCSF), Benioff Children's Hospital, San Francisco, California, USA.
| | - R Simmons
- University of California, San Francisco (UCSF), Benioff Children's Hospital, San Francisco, California, USA
| |
Collapse
|
11
|
Reich K, Sullivan J, Arenberger P, Jazayeri S, Mrowietz U, Augustin M, Elewski B, You R, Regnault P, Frueh JA. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol 2020; 184:425-436. [PMID: 32479641 DOI: 10.1111/bjd.19262] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/27/2020] [Indexed: 11/30/2022]
Abstract
BACKGROUND Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, a cornerstone cytokine in psoriasis, has shown long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations. OBJECTIVES To report the long-term (2·5-year) efficacy and safety of secukinumab in nail psoriasis. METHODS TRANSFIGURE, a double-blind, randomized, placebo-controlled, parallel-group, multicentre phase IIIb study in 198 patients, investigated secukinumab 150 mg and 300 mg in patients with moderate-to-severe nail psoriasis. RESULTS At week 16, the primary endpoint Nail Psoriasis Severity Index (NAPSI) was met, demonstrating superiority of secukinumab to placebo. The effect was sustained over 2·5 years with a large benefit for nail clearance, with mean NAPSI improvement of -73·3% and -63·6% with secukinumab 300 mg and 150 mg, respectively. At 2·5 years, secukinumab demonstrated sustained clinically significant reductions in total mean Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) quality-of-life (QoL) scores of -52·4% and -18·1%, and 70% and 71% of patients achieved a weighted NAPPA Patient Benefit Index global score of ≥ 2 with secukinumab 300 mg and 150 mg, respectively. Patients showed considerable improvements in the EuroQol 5-Dimension health status questionnaire at 2·5 years, reporting a decrease in pain and discomfort. No new safety findings were observed. CONCLUSIONS Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2·5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile.
Collapse
Affiliation(s)
- K Reich
- Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,Skinflammation® Center, Hamburg, Germany
| | - J Sullivan
- Sutherland Hospital, University of New South Wales, Sydney, NSW, Australia
| | - P Arenberger
- Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - S Jazayeri
- Alliance Dermatology and Mohs Center, Phoenix, AZ, USA
| | - U Mrowietz
- Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany
| | | | - B Elewski
- Department of Dermatology, University of Alabama, Birmingham, AL, USA
| | - R You
- China Novartis Institutes for BioMedical Research, Shanghai, China
| | | | - J A Frueh
- Novartis Pharma AG, Basel, Switzerland
| |
Collapse
|
12
|
Alqahtani JS, Mendes RG, Aldhahir A, Rowley D, AlAhmari MD, Ntoumenopoulos G, Alghamdi SM, Sreedharan JK, Aldabayan YS, Oyelade T, Alrajeh A, Olivieri C, AlQuaimi M, Sullivan J, Almeshari MA, Esquinas A. Global Current Practices of Ventilatory Support Management in COVID-19 Patients: An International Survey. J Multidiscip Healthc 2020; 13:1635-1648. [PMID: 33239884 PMCID: PMC7680685 DOI: 10.2147/jmdh.s279031] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Accepted: 10/19/2020] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND As the global outbreak of COVID-19 continues to ravage the world, it is important to understand how frontline clinicians manage ventilatory support and the various limiting factors. METHODS An online survey composed of 32 questions was developed and validated by an international expert panel. RESULTS Overall, 502 respondents from 40 countries across six continents completed the survey. The mean number (±SD) of ICU beds was 64 ± 84. The most popular initial diagnostic tools used for treatment initiation were arterial blood gas (48%) and clinical presentation (37.5%), while the national COVID-19 guidelines were the most used (61.2%). High flow nasal cannula (HFNC) (53.8%), non-invasive ventilation (NIV) (47%), and invasive mechanical ventilation (IMV) (92%) were mostly used for mild, moderate, and severe COVID-19 cases, respectively. However, only 38.8%, 56.6% and 82.9% of the respondents had standard protocols for HFNC, NIV, and IMV, respectively. The most frequently used modes of IMV and NIV were volume control (VC) (36.1%) and continuous positive airway pressure/pressure support (CPAP/PS) (40.6%). About 54% of the respondents did not adhere to the recommended, regular ventilator check interval. The majority of the respondents (85.7%) used proning with IMV, with 48.4% using it for 12-16 hours, and 46.2% had tried awake proning in combination with HFNC or NIV. Increased staff workload (45.02%), lack of trained staff (44.22%) and shortage of personal protective equipment (PPE) (42.63%) were the main barriers to COVID-19 management. CONCLUSION Our results show that general clinical practices involving ventilatory support were highly heterogeneous, with limited use of standard protocols and most frontline clinicians depending on isolated and varied management guidelines. We found increased staff workload, lack of trained staff and shortage of PPE to be the main limiting factors affecting global COVID-19 ventilatory support management.
Collapse
Affiliation(s)
- Jaber S Alqahtani
- UCL Respiratory, University College London, London, UK
- Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dammam, Saudi Arabia
| | - Renata G Mendes
- Department of Physical Therapy, Cardiopulmonary Physiotherapy Laboratory, Federal University of São Carlos, São Paulo, Brazil
| | - Abdulelah Aldhahir
- UCL Respiratory, University College London, London, UK
- Respiratory Care Department, Faculty of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia
| | - Daniel Rowley
- Pulmonary Diagnostics & Respiratory Therapy Services, University of Virginia Medical Center, Charlottesville, VA, USA
| | - Mohammed D AlAhmari
- Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dammam, Saudi Arabia
- Dammam Health Network, Dammam, Saudi Arabia
| | - George Ntoumenopoulos
- Consultant Physiotherapist, Physiotherapy Department St Vincent’s Hospital Sydney, Sydney, NSW, Australia
| | - Saeed M Alghamdi
- National Heart and Lung Institute, Imperial College London, London, UK
- Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia
| | - Jithin K Sreedharan
- Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dammam, Saudi Arabia
| | | | - Tope Oyelade
- UCL Institute for Liver and Digestive Health, London, UK
| | - Ahmed Alrajeh
- Respiratory Care, King Faisal University, Al-Ahsa, Saudi Arabia
| | - Carlo Olivieri
- Emergency Department, Ospedale Sant’Andrea, Vercelli13100, Italy
| | - Maher AlQuaimi
- Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
| | - Jerome Sullivan
- President, International Council for Respiratory Care, Professor Emeritus & Respiratory Care Program Director, The University of Toledo, Toledo, OH, USA
| | - Mohammed A Almeshari
- Rehabilitation Health Sciences Department, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia
| | - Antonio Esquinas
- Director International NIV School, Intensive Care Unit, Hospital Morales Meseguer, Murcia, Spain
| |
Collapse
|
13
|
Chick J, Mitchell A, Sullivan J, Herbert T, Lawes R, McNair H, Schmidt M, Nill S, Kirby A, Oelfke U. PO-1766: A clinical solution for electron streaming shielding for partial breast treatments on Unity MRlinac. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01784-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
Martinez S, Deering S, Sullivan J, Pasquale C, Shumard T, Clark B, Amdur A, Malanga V, Malanga E, Yawn B, Stepnowsky C. 0696 The O2VERLAP Study: High Cpap Use Levels Found In Overlap Syndrome (OSA And COPD) Patients. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
CPAP therapy is prescribed to help manage disordered breathing during sleep time periods. Most users, especially those with non-severe obstructive sleep apnea (OSA), use it only for some portion of their sleep period. Patients with Overlap Syndrome have both OSA and chronic obstructive pulmonary disease (COPD). While there has been some research on CPAP use levels in this patient population, there has been little indication that they use CPAP any differently than those with OSA only.
Methods
The O2VERLAP Study was a large comparative effectiveness trial enrolling people with COPD and OSA and using two different methods of providing information and support to current users of CPAP therapy. The study utilized an electronic national recruitment strategy and 332 participants were enrolled. CPAP data from the 12-week study period was analyzed. The Pittsburgh Sleep Quality Index was used to determine both estimated total sleep period (TSP) and total sleep time (TST). Because participants were all current users of CPAP, data from the total sample was combined and used. The percentage of TST and TSP that CPAP was used was calculated as CPAP use divided by either TST or TSP.
Results
The mean TST was 6.8 hours, TSP was 8.1 hours, and CPAP use was 6.7 hours. CPAP was used during 98.5% of the TST and during 82.7% of the TSP. Over 35% of the sample used CPAP at a level that was equal to or greater than their total sleep period.
Conclusion
Most OSA study populations use CPAP for some fraction of their night’s sleep. This COPD/OSA study population used CPAP to a markedly high level, including over one-third of the sample (n=~100) who used CPAP more than their self-reported sleep period. Further research on the extent and reasons for non-sleep period (i.e., daytime) CPAP use in COPD patients is warranted.
Support
PPRND #1507-31666.
Collapse
Affiliation(s)
| | - S Deering
- VA San Diego Healthcare System, San Diego, CA
| | | | | | - T Shumard
- American Sleep Apnea Association, Washington, DC
| | | | - A Amdur
- American Sleep Apnea Association, Washington, DC
| | | | | | - B Yawn
- COPD Foundation, Miami, FL
| | - C Stepnowsky
- VA San Diego Healthcare System, San Diego, CA
- University of California at San Diego, La Jolla, CA
| |
Collapse
|
15
|
Gottlieb A, Kubanov A, Doorn M, Sullivan J, Papp K, You R, Regnault P, Frueh J. 苏金单抗治疗掌跖银屑病的研究. Br J Dermatol 2020. [DOI: 10.1111/bjd.18916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Logan A, Brenner A, Sullivan J, Patel K, Sharma N. Evaluation of Universal versus Preemptive Antifungal Prophylaxis in Lung Transplantation. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
17
|
Gottlieb A, Kubanov A, Doorn M, Sullivan J, Papp K, You R, Regnault P, Frueh J. A study of the drug secukinumab in the treatment of palmoplantar psoriasis. Br J Dermatol 2020. [DOI: 10.1111/bjd.18906] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
18
|
Gottlieb A, Kubanov A, Doorn M, Sullivan J, Papp K, You R, Regnault P, Frueh J. Sustained efficacy of secukinumab in patients with moderate‐to‐severe palmoplantar psoriasis: 2·5‐year results from
GESTURE
, a randomized, double‐blind, placebo‐controlled trial. Br J Dermatol 2019; 182:889-899. [DOI: 10.1111/bjd.18331] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/04/2019] [Indexed: 01/23/2023]
Affiliation(s)
- A.B. Gottlieb
- Department of Dermatology Icahn School of Medicine at Mount Sinai New York NY U.S.A
| | - A. Kubanov
- State Scientific Center of Dermatology, Venereology and Cosmetology Moscow Russia
| | - M. Doorn
- Department of Dermatology Erasmus University Medical Center Rotterdam the Netherlands
| | - J. Sullivan
- Kingsway Dermatology & Aesthetics Miranda Australia
| | - K.A. Papp
- K. Papp Research and Probity Medical Research, Inc. Waterloo ON Canada
| | - R. You
- China Novartis Institutes for BioMedical Research Shanghai China
| | | | | |
Collapse
|
19
|
GILLIS E, Sullivan J. SAT-131 ADVERSE FETAL OUTCOMES IN A RODENT MODEL OF PREGNANCY AFTER RECOVERY FROM ACUTE KIDNEY INJURY. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
20
|
Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, Parneix A, Regnault P, You R, Milutinovic M. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32‐week results from the randomized placebo‐controlled
TRANSFIGURE
trial. Br J Dermatol 2019; 181:954-966. [DOI: 10.1111/bjd.17351] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/21/2018] [Indexed: 12/14/2022]
Affiliation(s)
- K. Reich
- Dermatologikum Berlin Friedrichstraße 89 10117 Berlin Germany
- SCIderm Research Institute Hamburg Germany
| | - J. Sullivan
- Kingsway Dermatology & Aesthetics Miranda NSW Australia
| | - P. Arenberger
- Department of Dermatology Charles University Third Faculty of Medicine Prague Czech Republic
| | - U. Mrowietz
- Psoriasis Center at the Department of Dermatology University Medical Center Schleswig‐Holstein Campus Kiel Germany
| | - S. Jazayeri
- Alliance Dermatology and Mohs Center Phoenix AZ U.S.A
| | | | - A. Parneix
- Novartis Pharmaceuticals Corporation East Hanover NJ U.S.A
| | | | - R. You
- Beijing Novartis Pharma Co. Ltd Beijing China
| | | |
Collapse
|
21
|
Kube E, Hicken B, Moye J, Harris G, Sullivan J. MENTAL HEALTH INTEGRATION IN GERI PACT. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- E Kube
- Iora Primary Care, Glendale, Arizona, USA, Glendale, Arizona, United States
| | - B Hicken
- VA Salt Lake City, St. Lake City UT, USA
| | - J Moye
- ABPP, New England Geriatric Research Education and Clinical Center (GRECC); Department of Psychiatry, Harvard Medical School
| | - G Harris
- St. Louis VA Healthcare System,St. Louis MO, USA
| | - J Sullivan
- CHOIR VA Boston Healthcare System and BU School of Public Health, Boston MA, USA
| |
Collapse
|
22
|
Sullivan J, Adjognon O, Shay K, Harvey K, Yaksic E, Intrator O, Moye J, Solimeo S. GERIATRIC PATIENT-ALIGNED CARE TEAMS IN THE VETERANS HEALTH ADMINISTRATION: HOW ARE THEY STRUCTURED? Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- J Sullivan
- VA Boston Healthcare System & Boston University, Boston, Massachusetts, United States
| | - O Adjognon
- Center for Healthcare Organization and Implementation Research, VA Boston Healthcare System
| | - K Shay
- US Department of Veterans Affairs, Geriatrics and Extended Care Services (10P4G)
| | - K Harvey
- Center for Healthcare Organization and Implementation Research, VA Boston Healthcare System
| | | | - O Intrator
- GEC DAC, Canandaigua VA Medical Center,Canandaigua NY
| | | | - S Solimeo
- Center for Comprehensive Access & Delivery Research & Evaluation Center, Iowa City VA Health Care System, Iowa City, IA; Department of General Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA
| |
Collapse
|
23
|
Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather J, Yosipovitch G, Gottlieb A, Merola J, Callis Duffin K, Fretzin S, Osuntokun O, Burge R, Naegeli A, Yang F, Lin CY, Todd K, Potts Bleakman A. Ixekizumab efficacy and safety in moderate-to-severe genital psoriasis. Br J Dermatol 2018. [DOI: 10.1111/bjd.17168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather J, Yosipovitch G, Gottlieb A, Merola J, Callis Duffin K, Fretzin S, Osuntokun O, Burge R, Naegeli A, Yang F, Lin CY, Todd K, Potts Bleakman A. 伊赛珠单抗在中度至重度生殖器银屑病中的疗效和安全性. Br J Dermatol 2018. [DOI: 10.1111/bjd.17179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Lange R, Lippa S, French L, Gartner R, Driscoll A, Wright M, Bailie J, Nora D, Sullivan J, Varbedian N, Camelo-Lopez V, Cheselka J, Bellini P, Holzinger J, Walker H, Brandler B, Freud J, Schaper A, Reese M, Barnhart E, Casey K, Ndege V, Ramin D, Eshera Y, Robinson G, Brickell T. A - 60Ten Year Neurobehavioral Outcome Following Mild, Moderate, Severe, and Penetrating Traumatic Brain Injury in U.S. Military Service Members. Arch Clin Neuropsychol 2018. [DOI: 10.1093/arclin/acy061.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Brickell T, Lippa S, French L, Gartner R, Driscoll A, Wright M, Bailie J, Nora D, Sullivan J, Varbedian N, Camelo-Lopez V, Cheselka J, Bellini P, Holzinger J, Walker H, Brandler B, Freud J, Schaper A, Reese M, Barnhart E, Casey K, Ndege V, Ramin D, Eshera Y, Robinson G, Lange R. A - 46Post-Concussion Symptom Reporting within the First 5-Years of the Recovery Trajectory Following Uncomplicated Mild Traumatic Brain Injury: A Cross-Sectional Perspective. Arch Clin Neuropsychol 2018. [DOI: 10.1093/arclin/acy061.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather J, Yosipovitch G, Gottlieb A, Merola J, Callis Duffin K, Fretzin S, Osuntokun O, Burge R, Naegeli A, Yang F, Lin CY, Todd K, Potts Bleakman A. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol 2018; 179:844-852. [DOI: 10.1111/bjd.16736] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/29/2018] [Indexed: 11/27/2022]
Affiliation(s)
- C. Ryan
- Department of Dermatology; Blackrock Clinic; Dublin Ireland
| | - A. Menter
- Department of Dermatology; Baylor University Medical Center; Dallas TX U.S.A
| | - L. Guenther
- Guenther Dermatology Research Centre; London ON Canada
| | - A. Blauvelt
- Oregon Medical Research Center; Portland OR U.S.A
| | | | - K. Meeuwis
- Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands
| | | | | | - G. Yosipovitch
- Department of Dermatology and Itch Center; University of Miami School of Medicine; Miami FL U.S.A
| | - A.B. Gottlieb
- Department of Dermatology; New York Medical College at Metropolitan Hospital; New York NY U.S.A
| | - J.F. Merola
- Department of Dermatology and Medicine; Division of Rheumatology; Harvard Medical School Brigham and Women's Hospital; Boston MA U.S.A
| | - K. Callis Duffin
- Department of Dermatology; University of Utah School of Medicine; Salt Lake City UT U.S.A
| | - S. Fretzin
- Dawes Fretzin Dermatology Group; Indianapolis IN U.S.A
| | | | - R. Burge
- Eli Lilly and Company; Indianapolis IN U.S.A
| | | | - F.E. Yang
- Eli Lilly and Company; Indianapolis IN U.S.A
| | - C.-Y. Lin
- Eli Lilly and Company; Indianapolis IN U.S.A
| | - K. Todd
- Eli Lilly and Company; Indianapolis IN U.S.A
| | | | | |
Collapse
|
28
|
Sullivan J, Bernie H, Ortega Y, Mulhall J. 615 Comparative analysis of the natural history of de novo Peyronie’s Disease versus post-radical prostatectomy Peyronie’s Disease. J Sex Med 2018. [DOI: 10.1016/j.jsxm.2018.04.522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
29
|
Sivade Dumousseau M, Alonso-López D, Ammari M, Bradley G, Campbell NH, Ceol A, Cesareni G, Combe C, De Las Rivas J, Del-Toro N, Heimbach J, Hermjakob H, Jurisica I, Koch M, Licata L, Lovering RC, Lynn DJ, Meldal BHM, Micklem G, Panni S, Porras P, Ricard-Blum S, Roechert B, Salwinski L, Shrivastava A, Sullivan J, Thierry-Mieg N, Yehudi Y, Van Roey K, Orchard S. Encompassing new use cases - level 3.0 of the HUPO-PSI format for molecular interactions. BMC Bioinformatics 2018; 19:134. [PMID: 29642841 PMCID: PMC5896046 DOI: 10.1186/s12859-018-2118-1] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2017] [Accepted: 03/20/2018] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND Systems biologists study interaction data to understand the behaviour of whole cell systems, and their environment, at a molecular level. In order to effectively achieve this goal, it is critical that researchers have high quality interaction datasets available to them, in a standard data format, and also a suite of tools with which to analyse such data and form experimentally testable hypotheses from them. The PSI-MI XML standard interchange format was initially published in 2004, and expanded in 2007 to enable the download and interchange of molecular interaction data. PSI-XML2.5 was designed to describe experimental data and to date has fulfilled this basic requirement. However, new use cases have arisen that the format cannot properly accommodate. These include data abstracted from more than one publication such as allosteric/cooperative interactions and protein complexes, dynamic interactions and the need to link kinetic and affinity data to specific mutational changes. RESULTS The Molecular Interaction workgroup of the HUPO-PSI has extended the existing, well-used XML interchange format for molecular interaction data to meet new use cases and enable the capture of new data types, following extensive community consultation. PSI-MI XML3.0 expands the capabilities of the format beyond simple experimental data, with a concomitant update of the tool suite which serves this format. The format has been implemented by key data producers such as the International Molecular Exchange (IMEx) Consortium of protein interaction databases and the Complex Portal. CONCLUSIONS PSI-MI XML3.0 has been developed by the data producers, data users, tool developers and database providers who constitute the PSI-MI workgroup. This group now actively supports PSI-MI XML2.5 as the main interchange format for experimental data, PSI-MI XML3.0 which additionally handles more complex data types, and the simpler, tab-delimited MITAB2.5, 2.6 and 2.7 for rapid parsing and download.
Collapse
Affiliation(s)
- M Sivade Dumousseau
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
| | - D Alonso-López
- Cancer Research Center (CiC-IBMCC, CSIC/USAL/IBSAL), Consejo Superior de Investigaciones Científicas (CSIC) and Universidad de Salamanca (USAL), 37007, Salamanca, Spain
| | - M Ammari
- School of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, USA
| | | | - N H Campbell
- Institute of Cardiovascular Science, University College London, Rayne Building, 5 University Street, London, WC1E 6JF, UK
| | - A Ceol
- Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia (IIT), Via Adamello 16, I-20139, Milan, Italy
| | - G Cesareni
- Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, Rome, Italy
| | - C Combe
- Wellcome Trust Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh, EH9 3BF, UK
| | - J De Las Rivas
- Cancer Research Center (CiC-IBMCC, CSIC/USAL/IBSAL), Consejo Superior de Investigaciones Científicas (CSIC) and Universidad de Salamanca (USAL), 37007, Salamanca, Spain
| | - N Del-Toro
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
| | - J Heimbach
- Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK
- Department of Genetics, University of Cambridge, Cambridge, UK
| | - H Hermjakob
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, National Center for Protein Sciences (The PHOENIX Center, Beijing), Beijing, China
| | - I Jurisica
- Krembil Research Institute, University Health Network, Toronto, ON, M5T 2S8, Canada
- Departments of Medical Biophysics and Computer Science, University of Toronto, Toronto, ON, Canada
| | - M Koch
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
| | - L Licata
- Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, Rome, Italy
| | - R C Lovering
- Institute of Cardiovascular Science, University College London, Rayne Building, 5 University Street, London, WC1E 6JF, UK
| | - D J Lynn
- EMBL Australia Group, South Australian Health and Medical Research Institute, Adelaide, Australia
- School of Medicine, Flinders University, Bedford Park, Adelaide, Australia
| | - B H M Meldal
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
| | - G Micklem
- Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK
- Department of Genetics, University of Cambridge, Cambridge, UK
| | - S Panni
- Department of Biology, Ecology and Earth Sciences, Università della Calabria, Rende, Italy
| | - P Porras
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
| | - S Ricard-Blum
- Univ Lyon, University Claude Bernard Lyon 1, INSA Lyon, CPE, Institute of Molecular and Supramolecular Chemistry and Biochemistry (ICBMS), UMR 5246, F-69622, Villeurbanne, France
| | - B Roechert
- SIB Swiss Institute of Bioinformatics, Centre Medical Universitaire, 1 rue Michel Servet, 1211, Geneva 4, Switzerland
| | - L Salwinski
- UCLA-DOE Institute for Genomics and Proteomics, Los Angeles, USA
| | - A Shrivastava
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
| | - J Sullivan
- Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK
- Department of Genetics, University of Cambridge, Cambridge, UK
| | - N Thierry-Mieg
- TIMC-IMAG, CNRS, Univ. Grenoble Alpes, F-38000, Grenoble, France
| | - Y Yehudi
- Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK
- Department of Genetics, University of Cambridge, Cambridge, UK
| | - K Van Roey
- Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, D-69117, Heidelberg, Germany
| | - S Orchard
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK.
| |
Collapse
|
30
|
Sivade Dumousseau M, Koch M, Shrivastava A, Alonso-López D, De Las Rivas J, Del-Toro N, Combe CW, Meldal BHM, Heimbach J, Rappsilber J, Sullivan J, Yehudi Y, Orchard S. JAMI: a Java library for molecular interactions and data interoperability. BMC Bioinformatics 2018; 19:133. [PMID: 29642846 PMCID: PMC5896107 DOI: 10.1186/s12859-018-2119-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2017] [Accepted: 03/20/2018] [Indexed: 11/22/2022] Open
Abstract
Background A number of different molecular interactions data download formats now exist, designed to allow access to these valuable data by diverse user groups. These formats include the PSI-XML and MITAB standard interchange formats developed by Molecular Interaction workgroup of the HUPO-PSI in addition to other, use-specific downloads produced by other resources. The onus is currently on the user to ensure that a piece of software is capable of read/writing all necessary versions of each format. This problem may increase, as data providers strive to meet ever more sophisticated user demands and data types. Results A collaboration between EMBL-EBI and the University of Cambridge has produced JAMI, a single library to unify standard molecular interaction data formats such as PSI-MI XML and PSI-MITAB. The JAMI free, open-source library enables the development of molecular interaction computational tools and pipelines without the need to produce different versions of software to read different versions of the data formats. Conclusion Software and tools developed on top of the JAMI framework are able to integrate and support both PSI-MI XML and PSI-MITAB. The use of JAMI avoids the requirement to chain conversions between formats in order to reach a desired output format and prevents code and unit test duplication as the code becomes more modular. JAMI’s model interfaces are abstracted from the underlying format, hiding the complexity and requirements of each data format from developers using JAMI as a library.
Collapse
Affiliation(s)
- M Sivade Dumousseau
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
| | - M Koch
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
| | - A Shrivastava
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
| | - D Alonso-López
- Cancer Research Center (CiC-IBMCC, CSIC/USAL/IBSAL), Consejo Superior de Investigaciones Científicas (CSIC) and Universidad de Salamanca (USAL), 37007, Salamanca, Spain
| | - J De Las Rivas
- Cancer Research Center (CiC-IBMCC, CSIC/USAL/IBSAL), Consejo Superior de Investigaciones Científicas (CSIC) and Universidad de Salamanca (USAL), 37007, Salamanca, Spain
| | - N Del-Toro
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
| | - C W Combe
- Wellcome Trust Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh, EH9 3BF, UK
| | - B H M Meldal
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
| | - J Heimbach
- Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK.,Department of Genetics, University of Cambridge, Cambridge, UK
| | - J Rappsilber
- Wellcome Trust Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh, EH9 3BF, UK.,Bioanalytics, Institute for Biotechnology, Technische Universität Berlin, 13355, Berlin, Germany
| | - J Sullivan
- Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK.,Department of Genetics, University of Cambridge, Cambridge, UK
| | - Y Yehudi
- Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK.,Department of Genetics, University of Cambridge, Cambridge, UK
| | - S Orchard
- European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK.
| |
Collapse
|
31
|
Lucid M, Rankin A, Espíndola A, Chichester L, Ehlers S, Robinson L, Sullivan J. Taxonomy and biogeography of Hemphillia (Gastropoda: Pulmonata: Arionidae) in North American rainforests, with description of a new species (Skade’s jumping-slug, Hemphillia skadei sp. nov.). CAN J ZOOL 2018. [DOI: 10.1139/cjz-2017-0260] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Species diversity of the genus Hemphillia Bland and W.G. Binney, 1872 (jumping-slugs) was studied across its range in western North America’s inland temperate rainforests. The taxonomic relationships among jumping-slug populations were clarified by integrating morphological, molecular, and biogeographic approaches. A new species, Skade’s jumping-slug (Hemphillia skadei sp. nov.), was discovered in this process and is described herein. We base this taxonomic decision on molecular comparison of representatives from other Hemphillia species and four morphological characters that distinguish H. skadei from its sister species, the pale jumping-slug (Hemphillia camelus Pilsbry and Vanatta, 1897). The distribution of H. skadei and H. camelus is described along with the notable lack of detection of the marbled jumping-slug (Hemphillia danielsi Vanatta, 1914) within the primary survey area.
Collapse
Affiliation(s)
- M.K. Lucid
- Idaho Department of Fish and Game, 2885 Kathleen Avenue, Coeur d’Alene, ID 83815, USA
| | - A. Rankin
- Department of Biological Sciences, Life Sciences South 252, 875 Perimeter Drive MS 3051, University of Idaho, Moscow, ID 83844-3051, USA
| | - A. Espíndola
- Department of Biological Sciences, Life Sciences South 252, 875 Perimeter Drive MS 3051, University of Idaho, Moscow, ID 83844-3051, USA
| | - L. Chichester
- 209 Chestnut Springs Way, Williamston, SC 29697, USA
| | - S. Ehlers
- Idaho Department of Fish and Game, 2885 Kathleen Avenue, Coeur d’Alene, ID 83815, USA
| | - L. Robinson
- Idaho Department of Fish and Game, 2885 Kathleen Avenue, Coeur d’Alene, ID 83815, USA
| | - J. Sullivan
- Department of Biological Sciences, Life Sciences South 252, 875 Perimeter Drive MS 3051, University of Idaho, Moscow, ID 83844-3051, USA
| |
Collapse
|
32
|
Eaton KA, Lloyd HA, Wheeler M, Sullivan J, Klass C, Allen Y, Lambert-Humble S. Looking after the mouth - Evaluation of a pilot for a new approach to training care home carers in Kent, Surrey and Sussex. Br Dent J 2018; 221:31-6. [PMID: 27388088 DOI: 10.1038/sj.bdj.2016.497] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/07/2016] [Indexed: 11/09/2022]
Abstract
Objective This pilot study aimed to produce and evaluate training resources and training in oral health care, including oral hygiene, for carers in care homes in Surrey and Medway.Methods During two training days, for carers from these homes, short, interactive presentations were given on a range of topics relevant to oral health care and oral hygiene of older people, followed by practical training. Prior to any training all attendees completed a 39 question questionnaire to establish their baseline knowledge of oral health and hygiene. At the end of the training day they completed an evaluation form. Fourteen weeks later, they were visited at their place of work and completed the same questionnaire again. Differences in responses between baseline and after 14 weeks were statistically tested using the chi-squared test.Results Sixty-six carers attended the training sessions and 44 were followed up 14 weeks later. The results showed an improvement in carer knowledge at follow up. The majority of carers (36/44) spoke English as their first language. They had a mean age of 41 years, 37 were female and 7 male. They had worked as carers for a mean of 10.9 years (range 4 months-34 years). Over 90% stated that the training day fully met or exceeded their requirements and expectations.Conclusions The results indicated improvements in carer knowledge. However, the carers were atypical of carers in general, as they were self-selected and well-motivated. Nevertheless the content of the training day and the questionnaire should inform future work in this area.
Collapse
Affiliation(s)
- K A Eaton
- University of Leeds, Honourary Professor at the University of Kent, Health Education Kent Surrey and Sussex (HEKSS), Regional Dental Tutor Kent
| | - H A Lloyd
- Special Care Dentistry, Project Adviser HEKSS
| | - M Wheeler
- Training and Development Lead HEKSS; Honourary Senior Lecturer, University of Kent
| | - J Sullivan
- HEKSS, General Dental Practitioner, Folkestone, Kent
| | | | | | | |
Collapse
|
33
|
MacEwan JP, Gill TM, Johnson K, Doctor J, Sullivan J, Shim J, Goldman DP. Measuring Sarcopenia Severity in Older Adults and the Value of Effective Interventions. J Nutr Health Aging 2018; 22:1253-1258. [PMID: 30498834 PMCID: PMC6302764 DOI: 10.1007/s12603-018-1104-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Accepted: 04/30/2018] [Indexed: 11/25/2022]
Abstract
OBJECTIVES Little is known about the severity and long-term health and economic consequences of sarcopenia. We developed a sarcopenia index to measure severity in older Americans and estimated the long-term societal benefits generated by effective interventions to mitigate severity. DESIGN Using a micro-simulation model, we quantified the potential societal value generated in the US in 2010-2040 by reductions in sarcopenia severity in older adults. All analyses were performed in Stata and SAS. SETTING AND PARTICIPANTS Secondary data from the National Health and Nutrition Examination Survey (NHANES) (N = 1634) and Health and Retirement Study (HRS) (N = 952) were used to develop a sarcopenia severity index in older adults. MEASUREMENTS Multi-trait multi-method and factor analyses were used to validate and calibrate the sarcopenia severity index, which was modeled as a function of gait speed, walking without an assistive device, and moderate physical activity. RESULTS In representative elderly populations, reducing sarcopenia severity by improving gait speed by 0.1 m/s in those with gait speed under 0.8 m/s generated a cumulative benefit of $65B by 2040 (2015 dollars). Improving walking ability in those with walking difficulty generated cumulative social benefit of $787B by 2040. CONCLUSIONS Reducing sarcopenia severity would generate significant health and economic benefits to society-almost $800B in the most optimistic scenarios.
Collapse
Affiliation(s)
- J P MacEwan
- Joanna P. MacEwan, Precision Health Economics, 11100 Santa Monica Blvd. Suite 500, Los Angeles, CA 90025, Phone: 310-984-7718,
| | | | | | | | | | | | | |
Collapse
|
34
|
Aboumatar H, Naqibuddin M, Chung S, Adebowale H, Bone L, Brown T, Cooper LA, Gurses AP, Knowlton A, Kurtz D, Piet L, Putcha N, Rand C, Roter D, Shattuck E, Sylvester C, Urteaga-Fuentes A, Wise R, Wolff JL, Yang T, Hibbard J, Howell E, Myers M, Shea K, Sullivan J, Syron L, Wang NY, Pronovost P. Better Respiratory Education and Treatment Help Empower (BREATHE) study: Methodology and baseline characteristics of a randomized controlled trial testing a transitional care program to improve patient-centered care delivery among chronic obstructive pulmonary disease patients. Contemp Clin Trials 2017; 62:159-167. [PMID: 28887069 DOI: 10.1016/j.cct.2017.08.018] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Revised: 08/23/2017] [Accepted: 08/25/2017] [Indexed: 11/15/2022]
Abstract
BACKGROUND Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of hospitalizations. Interventional studies focusing on the hospital-to-home transition for COPD patients are few. In the BREATHE (Better Respiratory Education and Treatment Help Empower) study, we developed and tested a patient and family-centered transitional care program that helps prepare hospitalized COPD patients and their family caregivers to manage COPD at home. METHODS In the study's initial phase, we co-developed the BREATHE transitional care program with COPD patients, family-caregivers, and stakeholders. The program offers tailored services to address individual patients' needs and priorities at the hospital and for 3months post discharge. We tested the program in a single-blinded RCT with 240 COPD patients who were randomized to receive the program or 'usual care'. Program participants were offered the opportunity to invite a family caregiver, if available, to enroll with them into the study. The primary outcomes were the combined number of COPD-related hospitalizations and Emergency Department (ED) visits per participant at 6months post discharge, and the change in health-related quality of life over the 6months study period. Other measures include 'all cause' hospitalizations and ED visits; patient activation; self-efficacy; and, self-care behaviors. DISCUSSION Unlike 1month transitional care programs that focus on patients' post-acute care needs, the BREATHE program helps hospitalized COPD patients manage the post discharge period as well as prepare them for long term self-management of COPD. If proven effective, this program may offer a timely solution for hospitals in their attempts to reduce COPD rehospitalizations.
Collapse
Affiliation(s)
- H Aboumatar
- Armstrong Institute for Patient Safety and Quality, The Johns Hopkins School of Medicine, United States; Division of General Internal Medicine, Dept. of Medicine, Johns Hopkins University School of Medicine, United States; Department of Health, Behavior, and Society, Bloomberg School of Public Health, Johns Hopkins University, United States; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, United States.
| | - M Naqibuddin
- Armstrong Institute for Patient Safety and Quality, The Johns Hopkins School of Medicine, United States
| | - S Chung
- Armstrong Institute for Patient Safety and Quality, The Johns Hopkins School of Medicine, United States
| | - H Adebowale
- Johns Hopkins Bayview Medical Center, United States
| | - L Bone
- Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, United States; Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, United States
| | - T Brown
- Armstrong Institute for Patient Safety and Quality, The Johns Hopkins School of Medicine, United States
| | - L A Cooper
- Division of General Internal Medicine, Dept. of Medicine, Johns Hopkins University School of Medicine, United States; Department of Health, Behavior, and Society, Bloomberg School of Public Health, Johns Hopkins University, United States; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, United States
| | - A P Gurses
- Armstrong Institute for Patient Safety and Quality, The Johns Hopkins School of Medicine, United States; Anesthesiology and Critical Care, The Johns Hopkins School of Medicine, United States; Division of Health Sciences Informatics, The Johns Hopkins School of Medicine, United States; Malone Center for Engineering in Healthcare, Whiting School of Engineering, Johns Hopkins University, United States
| | - A Knowlton
- Department of Health, Behavior, and Society, Bloomberg School of Public Health, Johns Hopkins University, United States
| | - D Kurtz
- Johns Hopkins Bayview Medical Center, United States
| | - L Piet
- Johns Hopkins Bayview Medical Center, United States
| | - N Putcha
- Pulmonary and Critical Care Medicine, The Johns Hopkins School of Medicine, United States
| | - C Rand
- Pulmonary and Critical Care Medicine, The Johns Hopkins School of Medicine, United States
| | - D Roter
- Department of Health, Behavior, and Society, Bloomberg School of Public Health, Johns Hopkins University, United States; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, United States
| | - E Shattuck
- Patient Advocate/Co-investigator, BREATHE Project, United States
| | - C Sylvester
- Johns Hopkins Bayview Medical Center, United States
| | - A Urteaga-Fuentes
- Armstrong Institute for Patient Safety and Quality, The Johns Hopkins School of Medicine, United States
| | - R Wise
- Pulmonary and Critical Care Medicine, The Johns Hopkins School of Medicine, United States
| | - J L Wolff
- Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, United States
| | - T Yang
- Armstrong Institute for Patient Safety and Quality, The Johns Hopkins School of Medicine, United States
| | - J Hibbard
- Health Policy Research Group, University of Oregon
| | - E Howell
- Armstrong Institute for Patient Safety and Quality, The Johns Hopkins School of Medicine, United States; Johns Hopkins Bayview Medical Center, United States
| | - M Myers
- Johns Hopkins Home Care Group, United States
| | - K Shea
- Johns Hopkins Bayview Medical Center, United States
| | | | - L Syron
- Johns Hopkins Home Care Group, United States
| | - Nae-Yuh Wang
- Division of General Internal Medicine, Dept. of Medicine, Johns Hopkins University School of Medicine, United States; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, United States
| | - P Pronovost
- Armstrong Institute for Patient Safety and Quality, The Johns Hopkins School of Medicine, United States; Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, United States; Anesthesiology and Critical Care, The Johns Hopkins School of Medicine, United States
| | | |
Collapse
|
35
|
Fauth E, Sullivan J, Schaefer S. COGNITION, NOT LENGTH OF STAY, PREDICTS REHABILITATIVE IMPROVEMENT IN TRANSITIONAL CARE. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- E. Fauth
- Utah State University, Logan, Utah,
| | | | | |
Collapse
|
36
|
Kafle P, Sullivan J, Verocai GG, Kutz SJ. Experimental Life-Cycle of Varestrongylus eleguneniensis (Nematoda: Protostrongylidae) in a Captive Reindeer (Rangifer tarandus tarandus) and a Muskox (Ovibos moschatus moschatus). J Parasitol 2017; 103:584-587. [PMID: 28590168 DOI: 10.1645/17-19] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
The life-cycle of a recently described protostrongylid lungworm, Varestrongylus eleguneniensis, which infects caribou, muskoxen, and moose from Arctic and boreal regions of North America, was completed experimentally for the first time. A native North American slug species, Deroceras laeve, was infected with the first-stage larvae (L1) isolated from the feces of wild muskoxen to generate third-stage larvae (L3). These were administered to a captive reindeer calf (250 L3) and an adult captive muskox (380 L3). The prepatent periods for the reindeer and muskox were 56 and 72 days, respectively. Patency lasted for only 19 days in the reindeer, and fecal larval counts were very low (0.09-1.53 larvae per gram of feces). Patency in the muskox was at least 210 days, and likely over 653 days, and the fecal larval counts were higher (0.06-17.8 larvae per gram of feces). This work provides the first experimental completion of the life-cycle of V. eleguneniensis.
Collapse
Affiliation(s)
- P Kafle
- Department of Ecosystem and Public Health, Faculty of Veterinary Medicine, University of Calgary (UCVM). 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada. Correspondence should be sent to S. J. Kutz at:
| | - J Sullivan
- Department of Ecosystem and Public Health, Faculty of Veterinary Medicine, University of Calgary (UCVM). 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada. Correspondence should be sent to S. J. Kutz at:
| | - G G Verocai
- Department of Ecosystem and Public Health, Faculty of Veterinary Medicine, University of Calgary (UCVM). 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada. Correspondence should be sent to S. J. Kutz at:
| | - S J Kutz
- Department of Ecosystem and Public Health, Faculty of Veterinary Medicine, University of Calgary (UCVM). 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada. Correspondence should be sent to S. J. Kutz at:
| |
Collapse
|
37
|
Barger LK, O’Brien C, Sullivan J, Wang W, Lockley S, Qadri S, Rajaratnam SW, Czeisler CA. 1176 FATIGUE RISK MANAGEMENT PROGRAM INCREASES SLEEP AND ALERTNESS IN FIREFIGHTERS. Sleep 2017. [DOI: 10.1093/sleepj/zsx050.1175] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Grizzle RE, Ward KM, Peter CR, Cantwell M, Katz D, Sullivan J. Growth, morphometrics, and nutrient content of farmed eastern oysters, Crassostrea virginica (Gmelin), in New Hampshire, USA. Aquac Res 2017; 48:1525-1537. [PMID: 30123043 PMCID: PMC6093306 DOI: 10.1111/are.12988] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
When harvested, oysters represent a removal from the ecosystem of nutrients such as nitrogen (N) and carbon (C). A number of factors potentially affect nutrient content, but a quantitative understanding across the geographic range of the eastern oysters is lacking. The present study was designed to quantify the relationships among various metrics of farmed eastern oysters near its northern geographic range focusing on nutrient content. Hatchery-reared oysters were deployed in polyethylene bags at six sites, and were measured on multiple occasions from 2010-2012. A quadratic polynomial fit to the combined datasets for shell height indicated that on average a 'cocktail' size oyster (63 mm shell height) would be reached after 2 yr, and 'regular' size (76 mm) would require 3 yr. There were significant differences in growth rates and oyster nutrient content among the sites; means for %N in soft tissue ranged from 6.9 to 8.6, and 0.07 to 0.18 in shell. Percent N in soft tissue and shell were highest at two sites at the mouths of rivers with elevated dissolved inorganic N concentrations in the water. Grand means (all sites, seasons and years combined) of soft tissue N and C for regular size oysters were 7.3% and 38.5%, respectively; and for shell N and C were 0.13% and 12.0%, respectively. Our study extends the range of data on nutrient content of the eastern oyster to northern New England, and indicates that oyster size, seasonality, and nutrient concentration in ambient water potentially affect %N and %C content of oysters.
Collapse
Affiliation(s)
- R E Grizzle
- University of New Hampshire, Jackson Estuarine Laboratory, Durham, NH 03824 USA
| | - K M Ward
- University of New Hampshire, Jackson Estuarine Laboratory, Durham, NH 03824 USA
| | - C R Peter
- University of New Hampshire, Jackson Estuarine Laboratory, Durham, NH 03824 USA
| | - M Cantwell
- United States Environmental Protection Agency, Office of Research and Development, National Human and Environmental Effects Research Lab, Atlantic Ecology Division, Narragansett, RI 02882 USA
| | - D Katz
- United States Environmental Protection Agency, Office of Research and Development, National Human and Environmental Effects Research Lab, Atlantic Ecology Division, Narragansett, RI 02882 USA
| | - J Sullivan
- United States Environmental Protection Agency, Office of Research and Development, National Human and Environmental Effects Research Lab, Atlantic Ecology Division, Narragansett, RI 02882 USA
| |
Collapse
|
39
|
Yozawitz J, Kissin M, Szuchmacher M, Sullivan J, Nicastro J, Coppa G, Molmenti E. Splenorenal Arterial Bypass: Description of Technique and Case Example in an Instance of Renal Revascularization during Adrenalectomy for Adrenocortical Carcinoma. Int J Angiol 2016; 25:e89-e92. [PMID: 28031665 DOI: 10.1055/s-0034-1396947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Abstract
We present a patient with a 16 cm adrenocortical carcinoma that underwent a left adrenalectomy en bloc with resection of the involved segment of the left renal artery. A splenectomy and splenorenal bypass was performed to revascularize the left kidney. To our knowledge, this is the first instance in the literature of a splenorenal arterial bypass being reported for renal revascularization during an extirpative oncologic procedure. A 64-year-old male patient, with history significant for adrenocortical carcinoma, status post prior right adrenalectomy with partial right nephrectomy, presented for an elective left adrenalectomy. Preoperative work-up revealed an 11.4 × 13.2 × 16 cm left adrenal mass, most consistent with an adrenocortical carcinoma. At the time of surgery, the mass was found to be intimately adherent to the aorta at the takeoff of the left renal artery. Moreover, the left renal artery appeared to be coursing directly through the mass. The involved segment of the left renal artery was resected en bloc with the tumor. Because of concerns for a small and likely poorly functioning right renal remnant, a decision was made to attempt to salvage the left kidney. This was accomplished by performing a splenectomy and constructing a splenorenal bypass. Serial Duplex Doppler renal ultrasound studies were obtained over the first three postoperative days and demonstrated improved arterial waveforms. Serum creatinine reached a peak level of 3.76 mg/dL on postoperative day 3, and then began to slowly trend down to 3.37 mg/dL on the day of discharge (postoperative day7).
Collapse
Affiliation(s)
- J Yozawitz
- Department of Surgery, Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, New York
| | - M Kissin
- Department of Vascular Surgery, Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, New York
| | - M Szuchmacher
- Department of Vascular Surgery, Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, New York
| | - J Sullivan
- Department of Surgical Oncology, Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, New York
| | - J Nicastro
- Department of Surgery, Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, New York
| | - G Coppa
- Department of Surgery, Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, New York
| | - E Molmenti
- Department of Transplant Surgery, Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, New York
| |
Collapse
|
40
|
Mansur AH, Mitchell V, Sullivan J, O’Shea K, White L. P237 Lung function decline is associated with serum periostin level but not fractional exhaled nitric oxide or blood eosinophils in severe asthma. Thorax 2016. [DOI: 10.1136/thoraxjnl-2016-209333.380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
41
|
O'Reilly M, O'Reilly P, Sheahan J, Sullivan J, O'Reilly H, O'Reilly M. Neuromas as the cause of pain in the residual limbs of amputees. An ultrasound study. Clin Radiol 2016; 71:1068.e1-1068.e6. [DOI: 10.1016/j.crad.2016.05.022] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2015] [Revised: 05/12/2016] [Accepted: 05/31/2016] [Indexed: 11/24/2022]
|
42
|
Lange R, Lippa S, Brickell T, Gartner R, Dilay A, Driscoll A, Wright M, Pizzano B, Johnson L, Nora D, Mahatan H, Sullivan J, Thompson D. B-50The Natural History of Neurocognitive Outcome from the Sub-Acute Recovery Phase to 1-Year Post-Injury in Military-Related Mild-Moderate Traumatic Brain Injury. Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw043.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Lange R, Lippa S, French L, Gartner R, Dilay A, Driscoll A, Wright M, Pizzano B, Johnson L, Nora D, Mahatan H, Sullivan J, Thompson D. B-49Neuropsychological Outcome from Concurrent Posttraumatic Stress Disorder (PTSD) and Mild Traumatic Brain Injury in U.S. Military Service Members: A Cross-Sectional Perspective of Recovery in the First 12-Months of Injury. Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw043.124] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Brickell T, French L, Lange R, Bailie J, Gartner R, Dilay A, Driscoll A, Wright M, Pizzano B, Johnson L, Nora D, Mahatan H, Sullivan J. B-47Neurobehavioral Outcome 10-Years Following Mild-Moderate Traumatic Brain Injury in U.S. Military Service Members. Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw043.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, Parneix A, Regnault P, You R, Milutinovic M. FRI0460 Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from The Transfigure Study. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5018] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
46
|
Abstract
To investigate factors associated with residents’ choice of type of Medicaid-funded community residential care setting in western Washington State. Method: Prospective cohort design including residents new to any of three setting types (264 residents entering 170 different facilities), using data from state and Medicaid databases and in-person interviews. The authors used analysis of variance and multinomial logistic regression to examine bivariate associations and estimate effects of resident and facility characteristics on choice of facility type at baseline. Results: Several resident characteristics appear to be associated with choice of community residential care setting, including age, marital status, education, functional status, and reported memory and behavior problems. Facility policies differ significantly among types of facilities and also appear to be associated with choice of setting. Discussion: Selection processes operate in choice of community residential care setting, with residents choosing facility type based on the fit of their needs with facility characteristics.
Collapse
Affiliation(s)
- A E Sales
- Veterans Administration Puget Sound Health Care System, USA
| | | | | | | | | | | |
Collapse
|
47
|
Sullivan J, O’Shea K, Mansur A. P78 Study of mortality in severe and difficult to treat asthma. Thorax 2015. [DOI: 10.1136/thoraxjnl-2015-207770.215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Weksler B, Sullivan J. F-104RESECTION OF THYMIC CARCINOMA AND CARCINOID SHOULD INCLUDE NODAL SAMPLING. Interact Cardiovasc Thorac Surg 2015. [DOI: 10.1093/icvts/ivv204.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Sullivan J, Moskovic D, Nelson C, Levine L, Mulhall J. Peyronie's disease: urologist's knowledge base and practice patterns. Andrology 2014; 3:260-4. [DOI: 10.1111/andr.292] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Revised: 09/12/2014] [Accepted: 09/15/2014] [Indexed: 11/26/2022]
Affiliation(s)
- J. Sullivan
- Urology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - D. Moskovic
- Urology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - C. Nelson
- Urology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - L. Levine
- Urology; Rush University; Chicago IL USA
| | - J. Mulhall
- Urology; Memorial Sloan Kettering Cancer Center; New York NY USA
| |
Collapse
|
50
|
Lee J, Wang C, Jackson W, Vainshtein J, Sullivan J, Wang S, Worden F, Eisbruch A, Jolly S. Clinically-Relevant Body Composition Changes in Head and Neck Cancer Patients Undergoing Chemoradiation. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|